For research use only. Not for therapeutic Use.
Eltrombopag is an oral thrombopoietin receptor agonist used to treat thrombocytopenia (low platelet count) in patients with chronic immune thrombocytopenia (ITP), hepatitis C, and aplastic anemia. By stimulating the thrombopoietin receptor, Eltrombopag enhances platelet production in the bone marrow. This medication is also investigated for its potential use in other hematological disorders and is critical in conditions requiring platelet support during medical treatments or surgeries. Its efficacy and safety are key factors in ongoing clinical research.
| Catalog Number | A000109 |
| CAS Number | 496775-61-2 |
| Synonyms | NA |
| Molecular Formula | C25H22N4O4 |
| Purity | ≥95% |
| Target | Anti-infection |
| Solubility | >13.2mg/mL in DMSO |
| Storage | Store at -20℃ |
| IUPAC Name | 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid |
| InChI | 1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33) |
| InChIKey | XDXWLKQMMKQXPV-QYQHSDTDSA-N |
| SMILES | CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C |
